In our previous work, we demonstrated that activating mutations in JAK1, 2, and 3 mediate resistance to FLT3 inhibitor treatment in FLT3-mutated AML and lead to reactivation of CSF2RB [19]. The gene discussed is FLT3; the disease is acute myeloid leukemia.